Thornberry Nancy
SEC Form 4 insider trading activity
Thornberry Nancy has filed 4 SEC Form 4 filings (6 transaction rows) across 3 companies, including DNLI, SDGR, VRTX, with disclosures dating back to 2026. 4 of those filings fall inside the rolling window. Most recent filing: Sep 4, 2026.
On the most recent filing, Thornberry Nancy is listed as Director at Denali Therapeutics Inc. Inside the rolling window, Thornberry Nancy reported no open-market purchases and 1 open-market sale totaling $262K in DNLI.
Companies traded
Other insiders at DNLI
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$262K
reported sales (SEC code S)
Companies
3
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Thornberry Nancy made?
Thornberry Nancy has filed 4 SEC Form 4 filings (6 transaction rows) across 3 companies, including DNLI, SDGR, VRTX since 2026.
Which companies does Thornberry Nancy trade?
Thornberry Nancy has filed SEC Form 4 disclosures for 3 companies, including DNLI, SDGR, VRTX.
When was Thornberry Nancy's most recent SEC Form 4 filing?
Thornberry Nancy's most recent SEC Form 4 filing on Tracefour is dated Sep 4, 2026.
What is Thornberry Nancy's total buy and sell value in the current window?
Inside the rolling retention window, Thornberry Nancy bought $0 and sold $262K based on SEC Form 4 filings.
What was Thornberry Nancy's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 11,439 DNLI shares on 2026-09-02, worth $262K, per SEC Form 4 filings.